OncoImmune’s founders have identified a novel pathway that is a checkpoint for the development of a number of disease indications. Our lead molecule, CD24Fc, targets this pathway and efficiently modulate the immune response in animal models of GVHD, multiple sclerosis and rheumatoid arthritis. We have completed phase II clinical trial for GVHD and is launching a pivotal phase III clinical trial for the indication.
As part of global effort to confront COVID-19, OncoImmune has launched Phase III clinical trial, SAC-COVID, to use CD24Fc for the therapy of severe and critical COVID-19 patients requiring oxygen support.
In addition to our in-house flagship program on CD24Fc, OncoImmune is developing a pipeline of unique product candidates in immuno-oncology, inflammatory and autoimmune diseases.